A1713

What is claimed is:

- 1. A method for producing antibodies to a three-dimensional epitope of a bioactive human parathyroid hormone, comprising:
 - a) immunizing an animal with the bioactive human parathyroid hormone; and
 - b) recovering antibodies from the animal; whereby the antibodies specifically recognize the three-dimensional structure of the bioactive human parathyroid hormone.
- 2. The method of claim 1, further comprising immunizing the animal with the human parathyroid hormone a second time before recovering the antibodies from the animal.
- 3. The method of claim 1, wherein the human parathyroid hormone is coupled to a carrier.
- 20 4. The method of claim 3, wherein the carrier is keyhole limpet hemocyanin.
 - 5. The method of claim 1, wherein the bioactive human parathyroid hormone comprises SEQ ID NO: 1.
 - 6. The method of claim 1 or 2, further comprising isolating the antibodies.
- 7. The method of claim 6, wherein the antibodies are isolated by affinity chromatography.

25

- 8. The method of claim 7, wherein the antibodies are isolated by screening the antibodies with fragments of the human parathyroid hormone linked to a solid phase.
- 5 9. A method for producing antibodies that recognize and bind the bioactive, three-dimensional epitope of parathyroid hormone, comprising
 - a) immunizing an animal with parathyroid hormone;
 - b) immunizing the animal with parathyroid hormone a second time; and
 - c) recovering the antibodies from the animal, whereby the antibodies recognize and bind the bioactive, three-dimensional epitope of parathyroid hormone.
 - 10. The method of claim 9, wherein the parathyroid hormone is conjugated to a carrier.
 - 11. The method of claim 10, wherein the carrier is keyhole limpet hemocyanin.
 - 12. The method of claim 9, wherein the parathyroid hormone is human parathyroid hormone.
- 13. The method of claim 9, further comprising isolating the antibodies so recovered.
 - 14. The method of claim 13, wherein the antibodies are isolated by affinity chromatography.
- 30 15. The method of claim 14, wherein the antibodies are isolated by fragments of parathyroid hormone coupled to a solid phase.

- 16. The method of claim 15, wherein the fragments of parathyroid hormone are selected from the group consisting of amino acids 1-13, 13-34, and 39-84 of SEQ ID NO: 1.
- 17. The method of claim 15, wherein the antibodies are isolated by a fragment of parathyroid hormone consisting of amino acids 1-13 of SEQ ID NO: 1.
- 18. A method for producing antibodies that recognize and bind the bioactive, three-dimensional epitope of parathyroid hormone, comprising
 - a) immunizing an animal with parathyroid hormone, wherein the parathyroid hormone comprises amino acids 1-84 of SEQ ID NO: 1;
 - b) immunizing the animal with parathyroid hormone a second time; and
 - c) recovering the antibodies from the animal, whereby the antibodies recognize and bind the bioactive, three-dimensional epitope of parathyroid hormone.
- 19. The method of claim 18, further comprising isolating the antibodies so recovered.
- 25 20. The method of claim 18, wherein the bioactive three-dimensional epitope of parathyroid hormone consists of amino acids 1-13 of SEQ ID NO: 1.

25

- 21. A method for producing antibodies that recognize and bind the bioactive, three-dimensional amino terminus of parathyroid hormone, comprising
 - a) immunizing an animal with parathyroid hormone conjugated to a keyhole limpet hemocyanin, wherein the parathyroid hormone comprises amino acids 1-84 of SEQ ID NO: 1;
 - b) subsequently immunizing the animal with parathyroid hormone; and
 - c) recovering the antibodies from the animal, whereby the antibodies recognize and bind the bioactive, three-dimensional amino terminus of parathyroid hormone.
- 22. The method of claim 21, wherein the bioactive threedimensional amino terminus of parathyroid hormone consists of amino acids 1-13 of SEQ ID NO: 1.
- 23. An isolated antibody that recognizes and binds the bioactive, three-dimensional epitope of parathyroid hormone.
- 24. The isolated antibody of claim 23, wherein the bioactive, three dimensional epitope is the amino terminus of parathyroid hormone.
- 25. The isolated antibody of claim 23, wherein the parathyroid hormone is human parathyroid hormone.
- 26. The isolated antibody of claim 23, wherein the bioactive, three-dimensional epitope consists of amino acids 1-13 of SEQ ID NO: 1.

- 27. An isolated antibody recognizing a peptide comprising an amino acid sequence from Ser in the 1 position to Lys in the 13 position of SEQ ID NO: 1.
- 5 28. An isolated antibody according to claim 27 recognizing a peptide consisting of an amino acid sequence from Ser in the 1 position to Lys in the 13 position of SEQ ID NO: 1.
 - 29. An antibody that is immunoreactive with the bioactive amino-terminal portion of human parathyroid hormone.
 - 30. The antibody of claim 29, wherein the bioactive aminoterminal portion comprises amino acids 1-13 of SEQ ID NO: 1.
 - 31. The antibody of claim 29, wherein the bioactive aminoterminal portion consists of amino acids 1-13 of SEQ ID NO: 1.
- 20 32. A therapeutic composition comprising the antibody of claim 29, and a pharmaceutically-acceptable carrier.
 - 33. The antibody of claim 29, wherein the antibody reduces adenylate cyclase activity by binding to the bioactive portion of the parathyroid hormone.
 - 34. Any one of the antibodies of claims 23-33, wherein the antibody is a polyclonal antibody.
- 30 35. Any one of the antibodies of claims 23-33, wherein the antibody is a monoclonal antibody.

- 36. Any one of the antibodies of claims 23-33, wherein the antibody is a humanized antibody.
- 37. Any one of the antibodies of claims 23-33, wherein the antibody is an antibody fragment.
 - 38. Any one of the antibodies of claims 23-33 coupled to a detectable marker.
 - 39. An antibody that specifically binds to the bioactive three-dimensional epitope of human parathyroid hormone, wherein the epitope consists of amino acids 1-13 of SEQ ID NO: 1.
 - 40. A polyclonal antibody that recognizes and binds the bioactive three-dimensional epitope of human parathyroid hormone produced by a process comprising the following steps:
 - a) immunizing an animal with human parathyroid hormone linked with keyhole limpet hemocyanin;
 - b) immunizing the animal with human parathyroid hormone; and
 - c) recovering the antibodies from the animal, whereby the antibodies recognize and bind the bioactive three-dimensional epitope of human parathyroid hormone.
 - 41. A polyclonal antibody that recognizes and binds the bioactive three-dimensional epitope of human parathyroid hormone produced by a process comprising the following steps:
- a) immunizing an animal with human parathyroid hormone linked with keyhole limpet hemocyanin;

5

- b) immunizing the animal with human parathyroid hormone; and
- c) recovering the antibodies from the animal, whereby the antibodies recognize and bind the bioactive three-dimensional epitope of human parathyroid hormone, and wherein the bioactive three-dimensional epitope consists of amino acids 1-13 of SEQ ID NO: 1.
- 42. An antibody selective for bioactive parathyroid hormone.
- 43. An antibody selective for bioactive parathyroid hormone, wherein the antibody recognizes and binds at least one of the first thirteen amino acids of SEQ ID NO: 1.
- 44. An isolated antibody that recognizes and binds the bioactive, three-dimensional epitope of parathyroid hormone, or a variant thereof.
- 45. An isolated antibody that recognizes and binds the bioactive, three-dimensional epitope of parathyroid hormone, or a fragment thereof.
- 46. A kit comprising an antibody that recognizes and binds the bioactive, three-dimensional epitope of parathyroid hormone.
 - 47. The kit of claim 46, wherein the antibody is coupled with a detectable label.
- 30 48. The kit of claim 46, wherein the bioactive, three-dimensional epitope consists of amino acids 1-13 of SEQ ID NO: 1.

25

- 49. The kit of claim 46, further comprising tools for obtaining a biological sample containing parathyroid hormone from a patient.
- 50. The kit of claim 47, wherein the detectable label is selected from the group consisting of chemiluminescent markers, fluorescent markers, radioactive markers, and enzymatic markers.
- 51. The kit of claim 47, wherein the detectable label is an acridinium ester.
- 52. A method for detecting bioactive parathyroid hormone in a sample, comprising
 - a) exposing the sample to an antibody that recognizes and binds the bioactive three-dimensional epitope of parathyroid hormone; and
 - b) detecting the antibody-hormone complex, thereby detecting the bioactive parathyroid hormone in the sample.
- 53. The method of claim 52, wherein the antibody that recognizes and binds the bioactive three-dimensional epitope of parathyroid hormone is coupled with a detectable marker.
- 54. The method of claim 52, further comprising exposing the antibody-hormone complex to another antibody that recognizes and binds parathyroid hormone before step (b).

- 55. A method for detecting bioactive parathyroid hormone in a sample, comprising
 - a) exposing the sample to a capture antibody that recognizes and binds the bioactive three-dimensional epitope of parathyroid hormone;
 - b) exposing the capture antibody-hormone complex to a detection antibody that binds a different epitope than the capture antibody; and
 - b) detecting the antibody-hormone complex, thereby detecting the bioactive parathyroid hormone in the sample.
- 56. The method of claim 55, wherein the detection antibody is coupled to a chemiluminescent marker.
- 57. The method of claim 56, wherein the chemiluminescent marker is an acridinium ester.
- 58. The method of claim 52 or 55, wherein the sample is from a patient with hyperparathyroidism.
- 59. The method of claim 52 or 55, wherein the sample is from a patient with hypoparathyroidism.
- 25 60. An immunoassay comprising an antibody that recognizes and binds the bioactive three-dimensional amino terminus of human parathyroid hormone.
- 61. The immunoassay of claim 60, wherein the bioactive threedimensional amino terminus consists of amino acids 1-13 of SEQ ID NO: 1.